Related Experiment Video
Updated: Apr 23, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.2K
Sex Differences in Levodopa-Sparing Effect of Safinamide: Post-hoc Findings from a Multicenter, Longitudinal,
Roberto Cilia1, Emanuele Cereda2, Fabiana Colucci1
1Parkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
Movement Disorders Clinical Practice
|April 22, 2026
Summary
Safinamide (100 mg) offers greater levodopa dose reduction in women with Parkinson's disease (PD). This finding supports personalized dopaminergic therapy, considering sex-specific responses in PD management.
Area of Science:
- Neurology
- Pharmacology
- Movement Disorders
Background:
- Female sex is a risk factor for levodopa-induced dyskinesias in Parkinson's disease (PD).
- Monoamine oxidase-B inhibitors (iMAO-B) are known for levodopa-sparing effects, but sex differences in response to safinamide are not well understood.
Purpose of the Study:
- To investigate potential sex differences in the levodopa-sparing effects of safinamide (100 mg) over a 9 ± 3 month period.
- To evaluate changes in levodopa dose and total levodopa-equivalent daily dose (LEDD) in relation to patient sex and safinamide treatment.
Main Methods:
- A cohort of 259 Parkinson's disease patients was analyzed, including 130 treated with safinamide (100 mg) and 129 controls not exposed to iMAO-B.
- The primary endpoint assessed the interaction between sex and treatment on the change in body weight-adjusted daily levodopa dose.
Main Results:
- Safinamide (100 mg) demonstrated efficacy by improving UPDRS-III scores and reducing OFF-time, irrespective of patient sex.
- A significant sex-by-treatment interaction was observed, indicating a greater reduction in weight-adjusted levodopa dose and total LEDD among women treated with safinamide (p=0.025 and p=0.045, respectively).
Conclusions:
- Safinamide (100 mg) exhibits a more pronounced levodopa-sparing effect in female Parkinson's disease patients.
- These findings underscore the importance of considering sex-specific factors for optimizing dopaminergic therapy in PD management.
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
917
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
917
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
377
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
377
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.9K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.9K
01:23Antidepressant Drugs: MAOIs and Other Agents
1.2K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.2K
01:14Pharmacokinetic–Pharmacodynamic Relationship: Duration of Dose-Effect Relationship
121
For drugs producing a quantal response, onset occurs when plasma concentration reaches a minimum effective level (Cmin). The drug's action duration depends on how long the plasma concentration remains above Cmin.Two primary factors influence this duration: dose size and the rate of drug removal from the action site. Both depend on the drug's redistribution to poorly perfused tissues and elimination processes. A larger dose promotes rapid onset and prolongs the effect's duration.Consider a...
121